PEIJIA-B Shares Surge Nearly 6% in Early Trading Following Exclusive Distribution Deal for SeQuent Please CIS

Stock News

Jun 16

PEIJIA-B shares experienced a significant rise of nearly 6% during the morning trading session. At the time of writing, the stock was up 2.23%, trading at HK$4.12 with a turnover of HK$4.0149 million.

The catalyst for the movement was a recent company announcement. The firm's subsidiary, Jiaqi Biotech, has entered into an exclusive distribution agreement with B. Braun Medical. Under the terms of this agreement, Jiaqi Biotech has secured the exclusive distribution rights for B. Braun's product, the SeQuent Please CIS Paclitaxel-Coated Intracranial Balloon Dilatation Catheter, within the Chinese mainland market.

This partnership with B. Braun is viewed as a strategic enhancement. It further diversifies the group's portfolio of neurointerventional products and strengthens its strategic positioning within the innovative intracranial intervention solutions sector.

CICC had previously commented on the company's outlook. The brokerage noted that as the commercialization of the firm's TaurusTrio anti-reflux valve gains momentum, and with several major innovative products—including the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair product GeminiOne—potentially receiving approval for market launch within 2026, the company's product portfolio in the structural heart disease field is expected to continue expanding. This is anticipated to further solidify the company's technological leadership and long-term competitive advantages.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1196934274"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196934274\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196934274?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 11:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196934274","market":"nz","top_or_hot":-1,"title":"PEIJIA-B Shares Surge Nearly 6% in Early Trading Following Exclusive Distribution Deal for SeQuent Please CIS","media":"Stock News","content":"<p>PEIJIA-B shares experienced a significant rise of nearly 6% during the morning trading session. At the time of writing, the stock was up 2.23%, trading at HK$4.12 with a turnover of HK$4.0149 million.<br><br>\nThe catalyst for the movement was a recent company announcement. The firm's subsidiary, Jiaqi Biotech, has entered into an exclusive distribution agreement with B. Braun Medical. Under the terms of this agreement, Jiaqi Biotech has secured the exclusive distribution rights for B. Braun's product, the SeQuent Please CIS Paclitaxel-Coated Intracranial Balloon Dilatation Catheter, within the Chinese mainland market.<br><br>\nThis partnership with B. Braun is viewed as a strategic enhancement. It further diversifies the group's portfolio of neurointerventional products and strengthens its strategic positioning within the innovative intracranial intervention solutions sector.<br><br>\n<b>CICC</b> had previously commented on the company's outlook. The brokerage noted that as the commercialization of the firm's TaurusTrio anti-reflux valve gains momentum, and with several major innovative products—including the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair product GeminiOne—potentially receiving approval for market launch within 2026, the company's product portfolio in the structural heart disease field is expected to continue expanding. This is anticipated to further solidify the company's technological leadership and long-term competitive advantages.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PEIJIA-B Shares Surge Nearly 6% in Early Trading Following Exclusive Distribution Deal for SeQuent Please CIS</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPEIJIA-B Shares Surge Nearly 6% in Early Trading Following Exclusive Distribution Deal for SeQuent Please CIS\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-16 11:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEIJIA-B shares experienced a significant rise of nearly 6% during the morning trading session. At the time of writing, the stock was up 2.23%, trading at HK$4.12 with a turnover of HK$4.0149 million.<br><br>\nThe catalyst for the movement was a recent company announcement. The firm's subsidiary, Jiaqi Biotech, has entered into an exclusive distribution agreement with B. Braun Medical. Under the terms of this agreement, Jiaqi Biotech has secured the exclusive distribution rights for B. Braun's product, the SeQuent Please CIS Paclitaxel-Coated Intracranial Balloon Dilatation Catheter, within the Chinese mainland market.<br><br>\nThis partnership with B. Braun is viewed as a strategic enhancement. It further diversifies the group's portfolio of neurointerventional products and strengthens its strategic positioning within the innovative intracranial intervention solutions sector.<br><br>\n<b>CICC</b> had previously commented on the company's outlook. The brokerage noted that as the commercialization of the firm's TaurusTrio anti-reflux valve gains momentum, and with several major innovative products—including the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair product GeminiOne—potentially receiving approval for market launch within 2026, the company's product portfolio in the structural heart disease field is expected to continue expanding. This is anticipated to further solidify the company's technological leadership and long-term competitive advantages.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159891","symbol_name":"医疗","start_time":0,"source_url":"","article_id":"1196934274","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196934274","pubTimestamp":1781580863,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"PEIJIA-B shares experienced a significant rise of nearly 6% during the morning trading session. At the time of writing, the stock was up 2.23%, trading at HK$4.12 with a turnover of HK$4.0149...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159891":"医疗","VXUS":"国际股票ETF-Vanguard","BK1583":"高瓴概念","BK1100":"医疗保健设备","BK4588":"碎股","09996":"沛嘉医疗-B","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股"},"translate_title":"继SeQuent Please CIS独家经销协议后，沛嘉-B股价早盘飙升近6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159891":1,"VXUS":1,"09996":1},"content_text":"PEIJIA-B shares experienced a significant rise of nearly 6% during the morning trading session. At the time of writing, the stock was up 2.23%, trading at HK$4.12 with a turnover of HK$4.0149 million.\nThe catalyst for the movement was a recent company announcement. The firm's subsidiary, Jiaqi Biotech, has entered into an exclusive distribution agreement with B. Braun Medical. Under the terms of this agreement, Jiaqi Biotech has secured the exclusive distribution rights for B. Braun's product, the SeQuent Please CIS Paclitaxel-Coated Intracranial Balloon Dilatation Catheter, within the Chinese mainland market.\nThis partnership with B. Braun is viewed as a strategic enhancement. It further diversifies the group's portfolio of neurointerventional products and strengthens its strategic positioning within the innovative intracranial intervention solutions sector.\nCICC had previously commented on the company's outlook. The brokerage noted that as the commercialization of the firm's TaurusTrio anti-reflux valve gains momentum, and with several major innovative products—including the third-generation TAVR product TaurusNXT and the mitral valve edge-to-edge repair product GeminiOne—potentially receiving approval for market launch within 2026, the company's product portfolio in the structural heart disease field is expected to continue expanding. This is anticipated to further solidify the company's technological leadership and long-term competitive advantages.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}